{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"}],"units":"Participants"}],"description":"Complete response = Absence of detectable monoclonal protein in serum or urine by immunofixation electrophoresis, less than 5% plasma cells on bone marrow biopsy without clonal dominance of kappa or lambda isotype, and normal serum free light chain assay.\n\nPartial response= For patients with detectable and quantifiable monoclonal marrow plasmacytosis= a reduction of 50% or more in plasma cells as a percentage of nucleated bone marrow cells. For patients with a detectable monoclonal peak on serum or urine protein electrophoresis= a reduction in the peak height of 50% or more.\n\nFor patients with quantifiable urinary kappa or lambda chain concentration= a 50% reduction in daily light chain excretion in 24 hour urine.\n\nFor patients with an elevated serum free light chain assay, a reduction of 50% or more.","groups":[{"description":"lenalidomide 15 mg/day, for 21 days with 7 days rest (28 day cycle) with or without dexamethasone 20 mg daily (10 mg BID) on Days 1-4, 9-12, and 17-20 of every other 28-day cycle.\n\ndexamethasone: dexamethasone 20 mg daily (10 mg BID) on Days 1-4, 9-12, and 17-20 of every other 28-day cycle.\n\nlenalidomide: 15 mg/day, for 21 days with 7 days rest (28 day cycle) with or without dexamethasone","id":"OG000","title":"Revlimid"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Participants who received at least 3 cycles of single-agent CC-5013 and underwent subsequent evaluation.","reportingStatus":"POSTED","timeFrame":"3 months","title":"Number of Patients With Hematologic Response With Single-agent CC-5013","type":"PRIMARY","unitOfMeasure":"Participants"}